Apoha has emerged from stealth with $36 million to build what it calls “Liquid State Intelligence” — a data layer for measuring how molecules, materials and formulations behave in the real world.
The round was led by Singular, with participation from Draper Associates, Redalpine, Seedcamp, Wilbe, Nucleus and grant funding from Innovate UK.
Founded in 2021 by Shamit Shrivastava and Anshika Srivastava, Apoha is trying to fill a gap in molecular science. Researchers can already analyse a molecule’s sequence and structure. Apoha wants to measure its behaviour: how it responds to stress, liquids and real-world conditions.
Its first product, VIBE, uses tiny samples to generate more than 1,000 empirical descriptors of molecular behaviour within minutes. The company says the platform can help spot drug candidates likely to fail before they reach expensive clinical trials.
Apoha is already working with Boehringer Ingelheim, where joint research showed its platform could identify high-risk antibody candidates with more than 90% precision from as little as 8 micrograms of material. It also says it outperformed 12 standard pharma tests on a 236-antibody benchmark dataset.
The company is targeting pharma first, but says the same approach can be used in food, materials and physical-world AI, essentially giving machines a way to “feel” how matter behaves, rather than just read or model it.
Apoha has operations in London and San Francisco and claims more than 60 patents across hardware, software, data and AI models.
